Phacilitate

  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Back
  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Join Today
Sign In
Sign In
Join Today

More results...

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
page
acf-ui-options-page
omapi
acf-taxonomy
acf-post-type
pha_member
lgx_lsp_shortcodes
speaker
e-book

ReiThera Opens New Large-Scale Viral Vector Manufacturing Facility

Banner
Watch On Demand
Anna Osborne
10 January 2023
SHARE NOW
Cell Therapy
Gene Therapy
GMP
Scaling Up
Skills, Talent & Development
Viral/Non-Viral Vectors
Leading contract development and manufacturing organization (CDMO) ReiThera has announced that it has received operational authorization from the Italian Medicines Agency (AIFA) to open a new facility for the large-scale production of viral vectors for vaccines and gene therapies. 

ReiThera’s Chief of Technology Stefano Colloca sat down with Phacilitate to tell us about ReiThera’s journey and the impact of its new facilities, ahead of its exhibition appearance at Advanced Therapies Week 2023!

Located at ReiThera’s pharmaceutical facility at the Castel Romano Technopole, construction of this specialized production area began back in May 2020 – following ReiThera’s investment of 15 million euros.

This 1,500 sq.m. world-class facility will provide space to meet the growing demand for manufacturing in this area, and provide ReiThera’s biotechnological clients, including both small and start-up companies as well as multinational pharma groups, access to advanced GMP technologies and maximum-scale-up flexibility.

The facility will feature the latest generation bioreactors with scaled volume capacities of 200, 1,000, and 2,000. This will accommodate the GMP production of therapeutics based on Adenovirus, Adeno-associated Virus, and Lentivirus, from 50 liters up to 3,000 liters.

How are you enjoying this news article? Let us know your thoughts, here >>

 

ReiThera is dedicated to the technical development, GMP manufacturing, and clinical translation of gene-based therapies including vaccines and medicinal products.

Scientists at ReiThera have developed an innovative platform based on simian adenoviral vectors that have multiple therapeutic applications. They have already successfully developed genetic vaccines against many major infectious diseases including HIV, hepatitis C, and malaria.

“Thanks to the operational authorization of this expanded facility, the ReiThera team, which combines high-level scientific knowledge with extensive experience in the engineering and bioprocessing of viral vectors, will be able to support companies engaged in the development of products in the field of vaccines and advanced therapies, from the fine-tuning of small-scale production processes to production on a commercial scale,” said Stefano Colloca, ReiThera CTO and Co-founder.

Developers at ReiThera are currently working on scalable platforms for other viral vectors including AAV, LV, MVA and HSV.

Source: ReiThera Press Release

You can catch the ReiThera team at Advanced Therapies Week 2023, Booth 629, Exhibit Show Floor!

Join us at Advanced Therapies Week >>


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.

More like this

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Lee Buckler, SVP Advanced Therapies, Blood Centers of America, Advanced Therapies Network, reflects on two decades of working within the advanced therapies industry as Phacilitate celebrates 20 years of operating in the field.
4 December 2023

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Oxford Biomedica Acquires ABL Europe from Institut Mérieux
6 December 2023

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

Two female pediatric patients with Rett syndrome were the first children worldwide to receive the promising treatment with Neurogene’s lead gene therapy product.
5 December 2023

Discover more like this

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

FDA Investigating ‘Serious Risk’ of Secondary Malignancy Linked to BCMA- or CD19-Directed CAR-T Immunotherapies

Sernova’s Hemophilia A Program Receives Orphan Drug and Rare Pediatric Disease Designations from FDA

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022